Browsing Tag
IMP761
2 posts
Immutep (ASX: IMM) surges 48% on FDA orphan drug designation: Is the STS pivot the new thesis?
Immutep (ASX: IMM) jumped 48% after the FDA granted orphan drug status for eftilagimod alfa in soft tissue sarcoma. Here is what the EFTISARC-NEO data means for the investment case.
Immutep taps Charles River for IMP761 LAG-3 antibody preclinical study
Immutep Limited, an Australian biotech company specializing in LAG-3 immunotherapies for cancer and autoimmune diseases, has partnered with…